Regression of Intracranial Meningiomas Following Treatment with Cabozantinib

Current Oncology

Ritesh R. Kotecha¹  Rupesh Kotecha²  Minesh P. Mehta²  Raees Tonse²  Haley Appel²  Yazmin Odia³  Guilherme Rabinowits³ 

[1] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA;Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA;

关键词: meningioma;    cabozantinib;    VEGF;    targeted therapy;   

DOI  :  10.3390/curroncol28020145

来源: DOAJ

【 摘 要 】

Recurrent meningiomas remain a substantial treatment challenge given the lack of effective therapeutic options aside from surgery and radiation therapy, which yield limited results in the retreatment situation. Systemic therapies have little effect, and responses are rare; the search for effective systemic therapeutics remains elusive. In this case report, we provide data regarding significant responses in two radiographically diagnosed intracranial meningiomas in a patient with concurrent thyroid carcinoma treated with cabozantinib, an oral multitarget tyrosine kinase inhibitor with potent activity against MET and VEGF receptor 2. Given the clinical experience supporting the role of VEGF agents as experimental therapeutics in meningioma and the current understanding of the biological pathways underlying meningioma growth, this may represent a new oral therapeutic alternative, warranting prospective evaluation.

【 授权许可】

Unknown